Abdominal obesity is associated with potassium depletion and changes in glucose homeostasis during diuretic therapy

Journal of Clinical Hypertension

Volumn 10, Issue 6, 2008, Pages 443-449

  Mariosa, Lydia Sebba Souza ^a,b   Ribeiro Filho, Fernando Flexa ^a   Batista, Marcelo Costa ^a   Hirota, Andréa Harumi ^a   Borges, Rodolfo Leão ^a   Ribeiro, Artur Beltrame ^a   Zanella, Maria Teresa ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; POTASSIUM; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; URIC ACID; DIURETIC AGENT;

ABDOMINAL OBESITY; ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DIURETIC THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; POTASSIUM DEPLETION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; ABDOMINAL FAT; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDY; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; OBESITY; STATISTICAL MODEL;

ABDOMINAL FAT; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DIURETICS; FEMALE; HUMANS; HYPERTENSION; HYPOKALEMIA; LINEAR MODELS; MALE; MIDDLE AGED; OBESITY; STATISTICS, NONPARAMETRIC;

EID: 55249085447     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.07817.x     Document Type: Article

References (46)

1. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27(10):2444-2449.
2. Ishizaka N, Ishizaka Y, Toda E, et al. Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy apanese individuals. Hypertens Res. 2005;28:27-34.
3. Wilsgaard T, Schirmer H, Arnesen E. Impact of body weight on blood pressure with a focus on sex differences. Arch Intern Med. 2000;160:2847-2853.
4. Sironi AM, Gastaldelli A, Mari A, et al. Visceral fat in hypertension: influence on insulin resistance and β-cell function. Hypertension. 2004;44:127-133.
5. Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460-468.
6. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000;102:179-184.
7. Hayashi T, Boyko EJ, Leonetti DL, et al. Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med. 2004;140:992-1000.
8. Boyko EJ, Fujimoto WY, Leonetti DL, et al. Visceral adiposity and risk of type 2 diabetes: A prospective study among Japanese Americans. Diabetes Care. 2000;23:465-471.
9. Goodpaster BH, Krishnaswami S, Harris TB, et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med. 2005;165:777-783.
10. Aneja A, El-Atat F, McFarlane SI, et al. Hypertension and obesity. Recent Prog Horm Res. 2004;59:169-205.
11. Boustany CM, Bharadwaj K, Daugherty A, et al. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol. 2004;287:R943-R949.
12. Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356-362.
13. Kassab S, Kato T, Wilkins C, et al. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension. 1995;25:893-897.
14. Shibao C, Gamboa A, Diedrich A, et al. Autonomic contribution to blood pressure and metabolism in obesity. Hypertension. 2007;49:27-33.
15. Giacchetti G, Faloia E, Mariniello B, et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens. 2002;15:381-388.
16. Karlsson C, Lindell K, Ottosson M, et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab. 1998;83:3925-3929.
17. Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001;15:2727-2729.
18. Paula RB, Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension. 2004;43:41-47.
19. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
20. Morales PAPA, Mitchell BD, Valdez RA, et al. Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects. The San Antonio Heart Study. Diabetes. 1993;42:154-161.
21. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: A link between hypertension, obesity, and glucose intolerance. J Clin Invest. 1985;75:809-817.
22. Prichard BNC, Owens CWI, Woolf AS. Adverse reactions to diuretics. Eur Heart J. 1992;13(suppl G):96-103.
23. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2987.
24. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet. 2007;369:201-207.
25. Zillich AJ, Garg J, Basu S et al. Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension. 2006;48:219-224.
26. Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes. 1983;32:106-111.
27. Plavinik FL, Rodrigues CI, Zanella MT, et al. Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. Hypertension. 1992;19(suppl 2):II26-II29.
28. Rowe JW, Tobin JD, Rosa RM, et al. Effects of experimental potassium deficiency on glucose and insulin metabolism. Metabolism. 1980;29:498-502.
29. Pollare T, Lithel H, Berne C. A comparison of the effects of hydroclortiazide and captopril on glucose and lipids metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
30. Gorden P, Sherman BM, Simopoulos AP. Glucose intolerance with hypokalemia: An incresead proportion of circulating proinsulin-like component. J Clin Endocrinol Metab. 1972;34:235-240.
31. Sandstrom PE. Inhibition by hydrochlorothiazide of insulin release and calcium influx in mouse pancreatic beta-cells. Br J Pharmacol. 1993;110:1359-1362.
32. Report of a WHO Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Geneva, Switzerland: World Health Organization, Departament of Noncommunicable Disease Surveillance; 1999:1-59.
33. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.
34. Levey AS, Bosh JP, Lewis JB, et al; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461-470.
35. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
36. Pearson TA, Mensah GA, Alexander W, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
37. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue. Arterioscler Thromb Vasc Biol. 1999;19(4):972-978.
38. Greenfield JR, Samaras K, Jenkins AB, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation. 2004;109:3022-3028.
39. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissue of obese subjects release interleukin 6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847-850.
40. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-1808.
41. Yamashita S, Matsuzawa Y, Tokunaga K, et al. Studies on the impaired metabolism of uric acid in obese subjects: Marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes. 1986;10:255-264.
42. Muscelli E, Natali A, Bianchi S, et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens. 1996;9:746-752.
43. Patt MR, Yanek LR, Moy TF, et al. Assessment of global coronary heart disease risk in overweight and obese African-American women. Obes Res. 2003;11:660-667.
44. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-969.
45. Shamiss A, Caroll J, Peleg E, et al. The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Am J Hypertens. 1995;8:276-281.
46. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802-809.